Pavunalimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.

**Synonyms:** - Anti-CTLA-4/Anti-LAG-3 Bispecific Monoclonal Antibody XmAb22841 - Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841 - BAVUNALIMAB - Bavunalimab - CTLA-4 x LAG-3 Bispecific Antibody XmAb22841 - XmAb 22841 - XmAb-22841 - XmAb22841